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Abstract
The European Leukemia Net (ELN) guidelines for treatment of myelodysplastic syndromes (MDS) connect heterogeneous MDS
subgroups with a number of therapeutic options ranging from best supportive care to allogeneic stem cell transplantation (alloSCT).
However, it is currently unknown whether adherence to guideline recommendations translates into improved survival. The sizeable
database of the Duesseldorf MDS Registry allowed us to address this question. We first performed a retrospective analysis including
1698 patients (cohort 1) to whom we retrospectively applied the ELN guidelines. We compared patients treated according to the
guidelines with patients who deviated from it, either because they received a certain treatment though it was not recommended or
because they did not receive that treatment despite being eligible. We also performed a prospective study with 381 patients (cohort 2)
whowere seen in our department and received guideline-based expert advice. Again, we compared the impact of subsequent guideline-
adherent versus non-adherent treatment. For the majority of treatment options (best supportive care, lenalidomide, hypomethylating
agents, low-dose chemotherapy, and intensive chemotherapy), we found that adherence to the ELNguidelines did not improve survival
in cohort 1. The samewas true when patient management was prospectively enhanced through guideline-based treatment advice given
by MDS experts (cohort 2). The only exceptions were alloSCT and iron chelation (ICT). Patients receiving ICT and alloSCT as
recommended fared significantly better than those whowere eligible but received other treatment. Our analysis underscores the limited
survival impact of most MDS therapies and suggests to pursue alloSCT in all suitable candidates.
Keywords Guideline adherence . Myelodysplastic syndrome . Hematopoietic stem cell transplantation . Iron chelation therapy .
Lenalidomide . Hypomethylating agents
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous
group of hematological malignancies that vary considerably
with regard to life expectancy. Prognosis depends on disease-
related as well as patient-related factors. Prognostic scoring
systems are generally built on disease-related factors and de-
signed to separate patients into risk groups. These risk groups
are utilized by guidelines to provide risk-adapted treatment
recommendations within the framework of approved drugs
and procedures. Guideline-based therapeutic decision-
making is enhanced by expert advice that takes patient-
related factors like performance status and comorbidities into
account. Widely accepted MDS guidelines that connect MDS
subtypes and risk groups with a number of therapeutic options
are the European LeukemiaNet (ELN) [1] guidelines for adult
patients with primary MDS, the National Comprehensive
Cancer Network (NCCN) guidelines for MDS [2], the
Key points
1. Adherence to well-accepted MDS guidelines did not yield a significant
survival advantage.
2. Eligible patients in whom alloSCT was carried out had superior
survival compared with eligible patients who did not undergo the
treatment.
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recommendations issued by the Nordic MDS Study Group
[3], and the recommendations for allogeneic hematopoietic
s tem cel l t ransplan ta t ion for MDS and chronic
myelomonocytic leukemia (CMML) issued by an internation-
al expert panel [4].
However, the survival impact of adherence to MDS guide-
lines and guideline-based expert advice is unknown. We ad-
dressed this question by analyzing adherence to ELN guide-
lines and MDS expert recommendations in the setting of the
large Duesseldorf MDS Registry.
Patients and methods
Cohort 1
Our retrospective analysis included 1659 patients in the
Duesseldorf MDS Registry who were diagnosed between
1982 and 2014 (cohort 1). The main purpose of this anal-
ysis was to evaluate the survival impact of adherence to
guidelines in clinical routine. As guidelines were not pub-
lished until 2006, clinical decision-making in our cohort 1
could not be guideline-based in a large proportion of
cases. Therefore, we retrospectively applied the current
ELN guidelines to define “guide-line adherent therapy.”
The following drugs and treatment modalities were eval-
uated: erythropoiesis stimulating agents (ESA), iron che-
lation therapy (ICT), red blood cell (RBC) and platelet
transfusions, lenalidomide, hypomethylating agents
(HMA), induction, and allogeneic stem cell transplanta-
tion (alloSCT). For each patient in cohort 1, we deter-
mined whether the received treatment was in accordance
with ELN guideline recommendations. We also paid at-
tention to drug approval status at the time of treatment
and determined whether treatment was in-label or off-la-
bel. Patients who received approved treatment they were
eligible for were classified as guideline-adherent and in-
label. In both cohorts, overall survival was used as the
primary endpoint. Overall survival of guideline-adherent
and non-adherent patients was finally compared using the
Kaplan-Meier method and the log rank test. The defined
starting point was the time of diagnosis. Furthermore,
1146 patients (69.8%) were treated in our department,
while 495 patients (30.2%) underwent treatment else-
where. No statistical difference in median overall survival
could be found between these two subgroups. Patients in
this cohort were followed for a median of 22 months (1–
500). Previous to comparing the subgroups in this cohort,
we performed analyses to check whether there are poten-
tial confounding factors. We investigated age, IPSS, and
MDS CI. Our analyses showed no significant difference
between these groups, which made them comparable. This
applies to all subgroups.
Cohort 2
Subsequently, we performed a prospective analysis on 381 addi-
tional patients (cohort 2) who first presented to the MDS outpa-
tient clinic at the University Hospital of Duesseldorf between
2015 and 2018. The objective of this analysis was to assess the
survival impact of adherence to guideline-based expert advice in
an outpatient setting. In order to document all first and follow-up
visits in a standardized manner, we established a tool that cap-
tures prognostic scores (International Prognostic Scoring System
(IPSS) [5], MDS Comorbidity Index (MDS CI) [6], and
Hematopoietic Stem Cell Transplantation Comorbidity Index
(HCT CI) [7]) and specific therapeutic advice given at each visit.
Documented therapeutic advice included watchful waiting, best
supportive care (transfusions, ICT, ESA), HMA, lenalidomide,
intensive and non-intensive chemotherapy, and alloSCT. We
then compared the outcome of patients who followed our thera-
peutic advice with patients who, for various reasons, did not. As
most of the interventions take a certain time to be started, a time-
dependent approach was applied: patients were classified as ad-
herent when the recommended therapeutic measure was initiated
within three months after the first visit. Potential candidates for
alloSCT were considered as adherent, when alloSCT was initi-
ated within a period of six months past their first visit in our
outpatient clinic. In this cohort, 44.9% of the patients (n = 171)
received treatment in our outpatient clinic, whereas 55.1% (n =
210) were treated elsewhere. Median overall survival did not
differ significantly between these two groups. Patients not treated
in our outpatient clinic were followed by contacting primary care
physicians and hematologists. In 5.2% of the patients, a compre-
hensive follow-up was not possible.
Cohort 2 was analyzed using a matching procedure. The fol-
lowing parameters were taken into account: age (± 7 years),
gender, blood cell counts, IPSS [5], andMDSCI [6]. For patients
undergoing alloSCT, the HCT CI [7] was also included. Again,
median overall survival was the major endpoint. Each treatment
was evaluated by comparingmedian overall survival in the entire
group of patients receiving the respective treatment with median
survival in a group of matched patients from a historical cohort
from the Duesseldorf MDS Registry who only received BSC. It
is known that MDS patients diagnosed after 2002 show a supe-
rior overall survival compared to patients diagnosed before 2002.
This effect is especially pronounced in patients with a high-risk
disease, but could also be verified in patients receiving BSC only
[8]. Thus, we split the matching partners in all therapeutic cate-
gories according to time of diagnosis using a cutoff at 2002 and
compared their OAS beforehand, to ensure that if matching part-
ners fared worse, it cannot be assigned to them not receiving
contemporary supportive care. For matching partners in all ex-
amined therapeutic categories, we could not find a significant
difference in OAS between the two groups. To enhance the
analysis, each treatment group was split into lower-risk and
higher-risk MDS. Lower-risk MDS included IPSS low and
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intermediate-1, whereas higher-risk MDS was defined by
intermediate-2 and high-risk according to IPSS. Due to this ap-
proach, subanalyses were restricted to a relatively low number of
patients. Patients included in this analysis were followed until
July 2018, with a median follow-up time of 14 months (1–195).
Results
Retrospective cohort (cohort 1)
Erythropoiesis stimulating agents
Patients receiving ESA according to the ELN guidelines versus
patients receiving ESA without guideline endorsement
When we looked at erythropoiesis stimulating factors, we
found that 57 patients in cohort 1 received erythropoiesis
stimulating agents (ESA) in-label and guideline-adherent,
while six patients were treated off-label. Patients treated
according to the guidelines lived for a median of 65
months (95%CI: 37.2; 97.8), while patients treated outside
the guidelines lived for a median of 173 months (95%CI:
0.0; 379.4). However, the difference was statistically not
significant (p = 0.099).
Patients receiving ESA according to the ELN guidelines versus
patients eligible for ESA treatment but not receiving it
We identified 15 patients who did not receive ESA despite being
eligible according to the guidelines. Their survival (median 29
months, 95%CI: 0.0; 70.8) was statistically not different from
that of the 57 patients receiving ESA according to the guidelines
(median 65 months, 95%CI: 37.2; 97.8) (p = 0.509).
Iron chelation therapy
Patients receiving ICT according to the ELN guidelines versus
patients receiving ICT without guideline endorsement
Fifty-three patients received ICT in-label and guideline-
adherent and lived for a median of 70 months (95%CI: 48;
92). In addition, 19 patients received ICT off-label and lived
for a median of 90 months (95%CI: 40.1; 139.9). The differ-
ence was statistically not significant (p = 0.652).
Patients receiving ICT according to the ELN guidelines versus
patients eligible for ICT but not receiving it
The group of 53 patients who were treated in-label and
guideline-adherent with an iron chelator achieved a survival
benefit compared with 24 patients who were eligible accord-
ing to the ELN guidelines but never received ICT (median
overall survival 70 months (95%CI: 48; 92) versus 32 months
(95%CI: 2.4; 61.6)). The difference was statistically signifi-
cant (p = 0.012, Fig. 1).
Lenalidomide
Patients receiving lenalidomide according to the ELN guide-
lines versus patients receiving lenalidomide without guide-
line endorsement
Sixteen patients received lenalidomide in accordance with the
ELN guidelines, with a median overall survival of 69 months
(95%CI: 47.86; 90.14). Their survival was not significantly dif-
ferent from 34 patients who did not meet the ELN criteria but
were still treated with lenalidomide (median 77 months, 95%CI:
34; 120) (p = 0.639). According to our review of documents,
these patients did not meet the ELN criteria because they received
lenalidomide despite not being RBC transfusion dependent.
Patients receiving lenalidomide according to the ELN guide-
lines versus patients eligible for lenalidomide treatment but
not receiving it
For the 16 patients receiving lenalidomide according to the
guidelines, survival was not significantly different when com-
pared to 13 patients who received only BSC despite being eligi-
ble for lenalidomide treatment (median overall survival 65
months (95%CI: 47.9; 90.1) versus 93 months (95%CI: 0.0;
210.4)) (p = 0.677).
Hypomethylating agents
Patients receiving HMAs according to the ELN guidelines ver-
sus patients receiving HMAs without guideline endorsement
Among 66 patients treated with azacitidine, only one patient
received it outside the guideline recommendations. We were
thus not able to formally compare guideline-adherent and non-
adherent treatment.
Patients receiving HMAs according to the ELN guidelines ver-
sus patients eligible for HMA treatment but not receiving it
Sixty-five patients were treated with azacitidine, whereas 100
patients were not treated even though they were eligible ac-
cording to the guidelines. The median overall survival of treat-
ed patients was 29 months (95%CI: 25.9; 32.1) while patients
who received best supportive care only lived for a median of
17 months (95%CI: 4.9; 29.1) (p = 0.399, Fig. 2).
Allogeneic stem cell transplantation
Patients undergoing alloSCT according to the ELN guidelines
versus patients receiving alloSCT without guideline endorse-
ment
The aforementioned therapies are all non-intensive. In con-
trast, alloSCT represents the most intensive and potentially
toxic but also potentially curative treatment applicable to
MDS patients. Cohort 1 included 118 patients undergoing
alloSCT in accordance with the ELN guidelines, whereas 40
patients did not meet the ELN guideline criteria but were still
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transplanted. In the latter group, 25 patients (62.5%) had only
mild cytopenias and a blast percentage below the required
threshold, or a favorable karyotype. Further, thirteen patients
(32.5%) with a low-risk IPSS underwent alloSCT, and two
patients (5.0%) were transplanted while being older than 70
years. The median survival of patients who were transplanted
despite not being formally eligible was 77 months (95%CI:
44.7; 109.4), compared to 65 months in guideline-adherent
patients (95%CI: 29.9; 100.1, p = 0.482, Fig. 3).
Patients undergoing alloSCT according to the ELN guidelines
versus patients eligible for alloSCT but not receiving it
While 118 patients underwent alloSCT in accordance with the
guidelines, 348 patients were not transplanted even though
they were eligible. Patients undergoing alloSCT lived signif-
icantly longer than patients who were eligible but were not
transplanted (p < 0.0005, Fig. 4). Median survival of patients
undergoing alloSCT was 65 months (95%CI: 29.9; 100.1)
compared to 16 months (95%CI: 13.6; 18.5) in patients who
received BSC only.
Fig. 1 Iron chelation therapy.
Comparison between guideline-
adherent patients and patients eli-
gible for but not receiving ICT
Fig. 2 Hypomethylating agents.
Comparison of guideline-
adherent patients and eligible pa-
tients not receiving HMAs
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Prospective cohort (cohort 2)
Watchful waiting
In cohort 2, 85 patients received the advice to watch and wait.
Since they were in no need for any treatment at their first visit,
they were simply asked to return for follow-up visits. Forty-
nine of them adhered to this recommendation, while 31 pa-
tients decided to try a more active approach. Fourteen patients
(45.2%) received BSC, and six (19.4%) were treated with
HMAs. Three patients (9.7%) received lenalidomide, and an-
other three underwent chemotherapy. Two non-adherent pa-
tients (6.5%) decided to undergo alloSCT. The alternative
therapeutic approach of three patients was unknown.
The non-adherent patients appeared to live longer (median
265 months (95%CI: 194.9; 335.6)) than the adherent patients
(91 months (95%CI: 67.8; 114.4)), but the difference was
statistically not significant (p = 0.799).
Fig. 3 AlloSCT. Comparison of
guideline-adherent patients and
patients undergoing alloSCT
without guideline endorsement
Fig. 4 AlloSCT. Comparison of
guideline-adherent patients and
patients not undergoing alloSCT
despite being eligible
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Best supportive care
Among 100 patients recommended to restrict treatment to best
supportive care, including RBC and platelet transfusions,
HGFs, and ICT, 84 were adherent, whereas 13 chose to try
more intensive treatment. Due to small numbers of patients in
the subgroups, a separate analysis for ICT as performed in the
retrospective cohort was not feasible. In this group, five pa-
tients (38.5%) decided to be treated with BSC. Four patients
(30.8%) underwent alloSCT and two (15.4%) received
azacitidine. Two patients (7.7%) were treated using
lenalidomide. The two groups did not differ significantly in
terms of overall survival (median 188 months (95%CI: 81.2;
294.8) versus 106 months (95%CI: 50.9; 161.1)) (p = 0.664).
Matched-pair analysis was not necessary for the comparison
between BSC and more intensive treatment, since all patients
in this group received BSC anyway.
Lenalidomide
Thirteen patients were recommended to start treatment
with lenalidomide, 9 of whom actually received this im-
munomodulatory drug while four did not. These four pa-
tients chose to receive BSC only. All patients were clas-
sified as lower-risk MDS. Since all patients were alive at
the end of the study, no conclusions could be drawn as to
a possible survival advantage. However, a matched-pair
analysis provided valuable clues. When matching the nine
adherent patients with 30 patients receiving BSC only, the
adherent patients showed a significant survival benefit
(median OS 182 months (95%CI: 148.7; 216.5) versus
73 months (95%CI: 40.2; 107.0)) (p = 0.004). Patients
in both of the groups had MDS del5q as defined by the
WHO.
Hypomethylating agents
Fifty-three patients were advised to be treated with azacitidine.
Comparing 33 adherent with 15 non-adherent patients, no
significant difference in survival was found (median OS 33
months (95%CI: 17.1; 58.8) versus 54 months (95%CI: 11.1;
96.6)) (p = 0.197). Nine patients (60%) decided to follow a
best supportive care concept; three (20%) underwent chemo-
therapy while another two (13.3%) were transplanted. One
patient (6.6%) did not receive any therapy at all. In five cases,
a comprehensive follow-up was not possible. Again, the
matching procedure yielded useful information and verified
the trend we showed in patients receiving HMAs in the retro-
spective group. Thirty-three adhering patients showed a high-
ly significant survival advantage over 128 matched patients
who received BSC but would have been eligible for treatment
with azacitidine as well (median OS 46 months (95%CI: 31.3;
60.7) versus 9 months (95%CI: 7.2; 10.8)) (p < 0.005, Fig. 5).
The 128 matching partners were part of a historical control
cohort. Since azacitidine was not yet approved at the time of
their first diagnosis, these patients did not receive a recom-
mendation for treatment with azacitidine.
Intensive and non-intensive chemotherapy
Of 16 patients who were advised to undergo chemotherapy,
nine received this treatment, while the other seven patients
opted for another therapeutic approach. Three patients
(42.9%) received azacitidine, while two (28.6%) decided for
BSC. Two other patients (28.6%) underwent alloSCT instead.
Overall survival was not significantly different (median 35
months (95%CI: 23.6; 46.6) versus 32 months (95%CI:
20.6; 43.6)) (p = 0.954). We were not able to identify
matching partners who only received BSC.
Allogeneic stem cell transplantation
Among 95 patients who were advised to undergo alloSCT, 63
patients were transplanted within six months, whereas 26 pa-
tients were treated differently. Nine patients (27.4%) decided
for BSC, another nine (27.4%) received HMAs. Four patients
(15.4%) decided for watchful waiting. Four patients (15.4%)
underwent chemotherapy. Due to comorbidities, eleven non-
adherent patients (42%) could not be transplanted. Seven pa-
tients (26%) declined the option of alloSCT due to various
personal reasons. For five other patients (19%), we were not
able to find a suitable donor within a period of six months.
Without applying our matching criteria, a survival benefit
of alloSCT was noted (median OS 74 months (95%CI:
25.05;122.95) versus 28 months (95%CI:7.52; 48.48)) (p =
0.015).
In our matched-pair analysis, 47 patients who underwent
alloSCT were compared with 73 matched patients who were
treated with BSC only. Transplanted patients achieved a high-
ly significant survival benefit compared with eligible patients
who did not undergo alloSCT (median OS 74 months
(95%CI: 24.4; 123.6) versus 15 months (95%CI: 7.8; 22.2))
(p < 0.0005, Fig. 6). As we were looking at a historical
matching cohort, it was not possible to ascertain why
alloSCT was not carried out in the latter patients who were
formally eligible according to guideline criteria.
Discussion
Due to strict eligibility criteria, MDS patients enrolled in clin-
ical trials are a selected subgroup not representative of the
entire patient population. Therefore, real-life evidence of the
survival impact of certain therapeutic approaches is sparse.
The Duesseldorf MDS Registry approximates the
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characteristics of the general MDS population and thus pro-
vides robust information about the clinical value of widely
used therapies.
When treating MDS patients, there are two major treat-
ment goals: to improve the patients’ quality of life mainly
with non-intensive measures and to prolong overall sur-
vival especially in high-risk MDS patients. However, low-
risk patients treated with BSC only with a durable hema-
tologic improvement tend to show superior overall surviv-
al as well, since one or more cytopenias are a primary
reason for morbidity as well as mortality. As improved
quality of live is closely associated to reduced mortality,
we chose overall survival as our major endpoint.
Furthermore, as the MDS CI adds prognostic information
independently from the IPSS, we used those two prognos-
tic scoring tools as the basis to classify our patients in
both cohorts.
Our retrospective analysis of 1658 patients in cohort 1 in-
dicates that patients eligible for a certain treatment did not gain
a significant survival benefit compared with patients who did
not receive it. The only exceptions were iron chelation therapy
among the non-intensive BSC options, and alloSCT. When
Fig. 6 AlloSCT. Comparison of
cumulative survival between
patients in the prospective cohort
receiving alloSCT and patients
receiving BSC only
Fig. 5 Hypomethylating agents.
Comparison of cumulative
survival between patients in the
prospective cohort receiving
HMA and patients receiving BSC
only
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used according to the ELN guidelines, these two treatments
conferred a significant survival advantage compared to the use
of BSC only. The favorable effect of iron chelation in patients
with lower-risk MDS may be attributable to the benefits of
diminished iron-related oxidative stress, including ameliora-
tion of ineffective erythropoiesis in a minority of patients [9].
AlloSCT is the only curative treatment, but most MDS pa-
tients are not fit enough to be eligible. As previously shown,
drugs like valproic acid, low-dose Ara-C, and antithymocyte
globulin (ATG) are only palliative [10]. According to our
analysis, the same is true for other therapies used these days,
which can help to decrease disease-related morbidity and en-
hance the patients’ quality of life but fail to achieve a substan-
tial gain in survival time.
It is therefore plausible that we failed to show a survival
advantage of guideline-adherent treatment. This applies to all
treatment categories examined. We found that a sizeable pro-
portion of patients (25% on average) were indeed treated out-
side the guidelines. This was true for non-intensive treatment
as well as alloSCT. Not being treated in strict accordance with
the guidelines did not lead to inferior outcome in any of the
therapeutic areas we analyzed. This observation supports the
view that clinical advice should be consistent with accepted
guidelines but should be free to include modifications accord-
ing to patient-related risk factors, geriatric evaluation, and
patient preferences.
In our prospective cohort including 381 patients seen in our
outpatient clinic (cohort 2), we confirmed that adherence to
guideline-based expert advice had no major impact on surviv-
al. Patients who chose to be treated differently had no inferior
prognosis, as long as their treatment exceeded best supportive
care. Again, the exception was alloSCT. In order to further
examine the value of various therapies, we used a matched-
pair procedure to compare guideline-adherent patients receiv-
ing a specific treatment with matched patients (historical con-
trols) who received BSC only. We showed that patients fol-
lowing guideline-based expert advice to undergo treatment
with lenalidomide, HMAs, or alloSCT did have a better prog-
nosis than patients who would have been eligible for such
treatment but received BSC only. This was true when treat-
ment was strictly according to the guidelines, as in our analy-
sis of cohort 1, or modified by expert advice.
Even in patients who do not derive a survival benefit from
treatment with lenalidomide or HMAs, such treatment may be
beneficial by improving blood counts and may even result in
temporary remission. Palliative treatment should thus not be
undervalued. If transfusion independency is achieved, this
will greatly improve the patients’ quality of life and also de-
crease the risk of cardiovascular complications associated
with chronic transfusion therapy in MDS [11, 12].
It is of importance that the presence of comorbidities per se
was not a criterion to exclude patients from our analyses.
According to the ELN guidelines, each patient in the
retrospective as well as in the prospective cohort was classi-
fied to match the respective therapeutic category. Therefore,
even comorbid patients were considered to receive a suitable
treatment and a selection bias on this level can be ruled out.
The groups receiving treatment were not younger and fitter.
Our findings do not invalidate the ELN guidelines but em-
phasize that proper patient management should go beyond
guidelines and should involve shared decision-making.
Guidelines should be considered a useful framework rather
than a dogma. Unfortunately, we were often unable to ascer-
tain the specific reasons for non-adherence to the guidelines,
mainly because many patients were managed outside our ter-
tiary referral center. Up to now, studies of interest validating
guidelines in hematology are sparse. Existing studies
concerning solid tumors focus on evaluating adherence to
one certain type of drug. A field of special interest is early
stage breast cancer. As the work about adherence to adjuvant
hormonal therapy [13] suggests, patients’ non-adherence is
associated with an increased risk of mortality. Nevertheless,
studies like this are far from evaluating adherence to an entire
guideline. The investigation of guideline use in other hemato-
logical entities such as acute myeloid leukemia or lymphoma
would be worthwhile, to gain important information on the
impact of adherence to patient related outcomes.
Altogether, our retrospective and prospective analyses im-
ply that, with the exception of alloSCT, none of the currently
available therapies is powerful enough to render deviation
from guideline-based expert advice a major disadvantage in
terms of prognosis. We clearly need better treatment options,
which can really make a change when correctly applied by an
MDS expert.
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